Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Thrombosis
Interventions: Not listed
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Sudden Cardiac Death
Interventions: Ovatio VR 6250 or DR6550; Device
Lead sponsor: LivaNova; Industry
Eligibility: Not listed
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 7
States / cities: Sheffield, Alabama • Tarzana, California • Atlanta, Georgia + 4 more

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 2 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 42
States / cities: Little Rock, Arkansas • Oakland, California • Orange, California + 31 more

Conditions: Cardiovascular Diseases, Sickle Cell Disease, Exercise
Interventions: Exercise Treatment Group; Other
Lead sponsor: Memorial Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Sickle Cell Disease Without Crisis
Interventions: G6PD Deficient Red Blood Cell Transfusion, Non-G6PD deficient Red Blood Cell Transfusion; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
Interventions: Buprenorphine Buccal Film [Belbuca]; Drug
Lead sponsor: Natasha Archer; Other
Eligibility: 12 Years to 22 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease
Interventions: Cogmed+; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 7 Years to 16 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Subjective Cognitive Decline, Depression in Old Age
Interventions: PeersCOG; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
Interventions: FLUDARABINE, CAMPATH-IH, Total Body Irradiation, FK506, G-SCF (Granulocyte-colony stimulating factor); Drug · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Day to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Race-related Stress, Depression, Anxiety, Quality of Life, Stress Reaction
Interventions: ACT for SCD; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 14 Years to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Interventions: Alemtuzumab, Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Cyclophosphamide, Sirolimus, Tacrolimus, Mycophenolate Mofetil, Plerixafor (mozobil); Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Iron, Abnormal Blood Level, Other Abnormal Blood Chemistry
Interventions: Fresh transfusion, Old transfusion; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Long QT Syndrome Type 3
Interventions: Eleclazine, Eleclazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Rochester, Minnesota • New York, New York • Rochester, New York

Conditions: Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
Interventions: Deferoxamine, Deferasirox, HIDA; Drug · Radiation
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episodes
Interventions: KindVR Aqua Program; Device
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 8 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Sickle Cell Disease
Interventions: Intravenous citrulline; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 6 Years to 50 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Sickle Cell Disease, Depression, Anxiety
Interventions: Computerized cognitive behavioral therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: acupuncture; Other
Lead sponsor: Deepika Darbari; Other
Eligibility: 8 Years to 22 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sickle Cell Disease
Interventions: Single Session Problem-Solving Intervention; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 7 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease
Interventions: Simvastatin; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 10 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Oakland, California

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound; Drug · Procedure
Lead sponsor: Versiti Blood Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • Milwaukee, Wisconsin

Conditions: Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions: Not listed
Lead sponsor: xCures; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Altos, California

Conditions: Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions: Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 27
States / cities: Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia, Hemoglobin SS, Hemoglobin SC, Hemoglobin Beta Thalassemia
Interventions: Decision Aid Tool, Standard Practice; Other
Lead sponsor: Emory University; Other
Eligibility: 8 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Sickle Cell Trait and the Risk of Venous Thromboembolism

Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications

A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients

Qualitative Survey of Potential Exercise Activity in Adults With Sickle Cell Anemia (SCA)

The Impact of Oxidative Stress on Erythrocyte Biology

Buprenorphine for the Management of Pain in Children With Sickle Cell Disease

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

Developing a Peer Support Intervention for Depression in SCD

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease

Allo HSCT for High Risk Hemoglobinopathies

Fresh Versus Old Red Blood Cells for Transfusion

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Pilot Study for Patients With Poor Response to Deferasirox

Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain

A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome

Cognitive Behavioral Therapy and Real-time Self-management Intervention for SCD Via Mobile Applications

Acupuncture for Pain in Sickle Cell Disease

Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease

Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease

Microvascular Blood Flow in Sickle Cell Anemia

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Decision Aid for Therapeutic Options In Sickle Cell Disease